No Data
Werewolf Therapeutics: Buy Rating Affirmed Amid Promising Clinical Advancements and Pipeline Potential
Werewolf Therapeutics Price Target Maintained With a $12.00/Share by JMP Securities
Werewolf Therapeutics Price Target Maintained With a $12.00/Share by JMP Securities
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
Werewolf Therapeutics (NASDAQ:HOWL) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table provides a quick ove
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics with a Buy and maintains $15 price target.
Buy Rating Affirmed for Werewolf Therapeutics Amid Promising Financials and Anticipated Clinical Updates
Express News | Werewolf Therapeutics Inc: Plans to Present Interim, First-in-Human Clinical Data From Ongoing Phase 1 Trial of Wtx-330 in Q2 of 2024